Long-term exposure to belatacept in recipients of extended criteria donor kidneys

American Journal of Transplantation

Volumn 13, Issue 11, 2013, Pages 2884-2891

  Charpentier, B ^a   Medina Pestana, J O ^b   Del C Rial, M ^c   Rostaing, L ^d   Grinyo J ^e   Vanrenterghem, Y ^f   Matas, A ^g   Zhang, R ^h   Muhlbacher F ⁱ   Pupim, L ^j   Florman, S ^k  

^a BICÊTRE HOSPITAL   (France)

^b HOSPITAL DO RIM E HIPERTENSÃO   (Brazil)

^c Instituto de Nefrologia Buenos Aires ar   (Argentina)

^d TOULOUSE UNIVERSITY HOSPITAL   (France)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g UNIVERSITY OF MINNESOTA   (United States)

^h TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^j BRISTOL MYERS SQUIBB   (United States)

^k MOUNT SINAI MEDICAL CENTER   (United States)

more..

Author keywords

Belatacept; cyclosporine A; kidney; renal function

Indexed keywords

BASILIXIMAB; BELATACEPT; CORTICOSTEROID; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ACUTE GRAFT REJECTION; ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM INFECTION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DEHYDRATION; DIARRHEA; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HEART ATRIUM FIBRILLATION; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; KIDNEY DONOR; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MYCOSIS; PNEUMONIA; POLYOMAVIRUS INFECTION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT; SKIN CANCER; SYSTOLIC BLOOD PRESSURE; URINARY TRACT INFECTION; VIRUS INFECTION;

BELATACEPT; CYCLOSPORINE A; KIDNEY; RENAL FUNCTION;

COHORT STUDIES; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; INTERNATIONAL AGENCIES; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; LIPIDS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; SAFETY; TIME FACTORS; TISSUE DONORS;

EID: 84886804102     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12459     Document Type: Article

References (34)

1. National Institute of Diabetes and Digestive and Kidney Diseases. Atlas of chronic kidney disease and end-stage renal disease in the United States. 2012. Available at: http://www.usrds.org/atlas.aspx. Accessed October 9, 2012.
2. Port FK, Wolfe RA, Mauger EA, Berling DP, Jiang K., Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA 1993; 270: 1339-1343.
3. Danovitch GM, Cohen DJ, Weir MR, et al. Current status of kidney and pancreas transplantation in the United States, 1994-2003. Am J Transplant 2005; 5: 904-915.
4. Metzger RA, Delmonico FL, Feng S, Port FK, Wynn JJ, Merion RM., Expanded criteria donors for kidney transplantation. Am J Transplant 2003; 3: 114-125.
5. Saidi RF, Elias N, Kawai T, et al. Outcome of kidney transplantation using expanded criteria donors and donation after cardiac death kidneys: Realities and costs. Am J Transplant 2007; 7: 2769-2774.
6. Halloran PF., Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715-2729.
7. Miller LW., Cardiovascular toxicities of immunosuppressive agents. Am J Transplant 2002; 2: 807-818.
8. Naesens M, Kuypers DR, Sarwal M., Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009; 4: 481-508.
9. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR., The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333.
10. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A Phase III study of belatacept-based immunosuppression regimens vs cyclosporine in renal transplant recipients (BENEFIT Study). Am J Transplant 2010; 10: 535-546.
11. Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10: 547-557.
12. Larsen CP, Grinyo J, Medina-Pestana J, et al. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-Year results from the BENEFIT and BENEFIT-EXT studies. Transplantation 2010; 90: 1528-1535.
13. Pestana JO, Grinyo JM, Vanrenterghem Y, et al. Three-year outcomes from BENEFIT-EXT: A phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant 2012; 12: 630-639.
14. Vanrenterghem Y, Bresnahan B, Campistol J, et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation 2011; 91: 976-983.
15. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535-546.
16. Vincenti F, Larsen CP, Alberu J, et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2012; 12: 210-217.
17. Durrbach A, Medina-Pestana JO, Pearson TC, et al. A Phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT Study). Am J Transplant 2010; 10: 547-557.
18. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D., A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
19. Levey AS, Coresh J, Greene T, et al. Expressing the MDRD study equation for estimating GFR with IDMS traceable (gold standard) serum creatinine values. J Am Soc Nephrol 2005; 16: 69A.
20. Ojo AO, Hanson JA, Meier-Kriesche H, et al. Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. J Am Soc Nephrol 2001; 12: 589-597.
21. Port FK, Bragg-Gresham JL, Metzger RA, et al. Donor characteristics associated with reduced graft survival: An approach to expanding the pool of kidney donors. Transplantation 2002; 74: 1281-1286.
22. Organ Procurement and Transplantation Network (OPTN), Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2010 Annual Data Report. 2010. Available at: http://www.srtr.org/annual-reports/2010/. Accessed October 11, 2012.
23. Gheorghian A, Schnitzler MA, Axelrod DA, Kalsekar A, L'Italien G, Lentine KL., The implications of acute rejection and reduced allograft function on health care expenditures in contemporary US kidney transplantation. Transplantation 2012; 94: 241-249.
24. Schnitzler MA, Johnston K, Axelrod D, Gheorghian A, Lentine KL., Associations of renal function at 1-year after kidney transplantation with subsequent return to dialysis, mortality, and healthcare costs. Transplantation 2011; 91: 1347-1356.
25. Ojo AO., Cardiovascular complications after renal transplantation and their prevention. Transplantation 2006; 82: 603-611.
26. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G., Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
27. Fellstrom B, Holdaas H, Jardine AG, et al. Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trial. Transplantation 2005; 79: 205-212.
28. Nankivell BJ, Chapman JR, Bonovas G, Gruenewald SM., Oral cyclosporine but not tacrolimus reduces renal transplant blood flow. Transplantation 2004; 77: 1457-1459.
29. Taler SJ, Textor SC, Canzanello VJ, Schwartz L., Cyclosporin-induced hypertension: Incidence, pathogenesis and management. Drug Saf 1999; 20: 437-449.
30. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070-1076.
31. Silva HT Jr, Yang HC, Abouljoud M, et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant 2007; 7: 595-608.
32. Vanrenterghem Y, Lebranchu Y, Hene R, Oppenheimer F, Ekberg H., Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation 2000; 70: 1352-1359.
33. Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB., Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 2005; 112: 3375-3383.
34. Grinyõ J, Charpentier B, Pestana JM, et al. An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation 2010; 90: 1521-1527.